CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 445 enrolled
Drug / intervention
Ibrutinib Oral Capsule +2 moredrug
Likely dose
Ibrutinib Oral Capsule 560mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02947347
NCT02947347Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

Pharmacyclics LLC.·interventional·Posted Oct 27, 2016·Updated Mar 17, 2026

In Brief

A Phase 3 clinical trial evaluating Ibrutinib Oral Capsule, Placebo, and 1 other intervention for Follicular Lymphoma. Completed, enrolled 445 participants across 128 sites in 19 countries.

Detailed Summary

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesAustralia, Austria, Belgium, Canada, Czechia, France, Greece, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Russia, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
CollaboratorsJanssen Research & Development, LLC

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 27, 2016
Enrollment StartJan 23, 2017
Primary CompletionFeb 21, 2024
Study CompletionJun 9, 2025
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 9.7 years ago

Interventions

Ibrutinib Oral Capsuledrug

Ibrutinib 560mg administered orally daily

Placebodrug

Placebo capsules to match ibrutinib administered orally daily

Rituximabdrug

Rituximab 375mg/m\^2 intravenously (IV) weekly